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Cartilage regeneration treatments using stem cells are associated with problems due to the cell source and the diﬃculty of delivering
the cells to the cartilage defect. We consider labeled induced pluripotent stem (iPS) cells to be an ideal source of cells for tissue
regeneration, and if iPS cells could be delivered only into cartilage defects, it would be possible to repair articular cartilage.
Consequently, we investigated the eﬀect of magnetically labeled iPS (m-iPS) cells delivered into an osteochondral defect by
magnetic ﬁeld on the repair of articular cartilage. iPS cells were labeled magnetically and assessed for maintenance of
pluripotency by their ability to form embryoid bodies in vitro and to form teratomas when injected subcutaneously into nude
rats. These cells were delivered speciﬁcally into cartilage defects in nude rats using a magnetic ﬁeld. The samples were graded
according to the histologic grading score for cartilage regeneration. m-iPS cells diﬀerentiated into three embryonic germ layers
and formed teratomas in the subcutaneous tissue. The histologic grading score was signiﬁcantly better in the treatment group
compared to the control group. m-iPS cells maintained pluripotency, and the magnetic delivery system proved useful and safe
for cartilage repair using iPS cells.
1. Introduction
Articular cartilage is known for its poor regenerative and
reparative ability, making repair diﬃcult after injury due to
insults such as trauma, osteoarthritis, or rheumatoid arthri-
tis. Current treatments for cartilage injury include conserva-
tive treatments such as rehabilitation, anti-inﬂammatory
analgesic medication, and intra-articular injection or
operative treatments such as bone marrow stimulating
techniques (drilling and microfracture) and autologous
osteochondral grafting [1, 2]. However, there are problems
associated with these methods. Bone marrow stimulating
techniques and autologous osteochondral grafting are unable
to completely restore hyaline cartilage. Cartilage regenera-
tion is one of the prime targets that remains largely
unsolved [1, 3].
Recently, there have been many reports of cartilage
regeneration treatment using stem cells. Recently reported
studies on cartilage regeneration have used MSCs, as well as
stem cells derived from adipose tissue, synovial tissue, and
peripheral blood [4–6]. Vega and collaborators reported
signiﬁcantly better function and cartilage quality in osteoar-
thritis patients treated with MSCs by intra-articular injection
[7]. However, major disadvantages of MSCs include limita-
tions in vitro proliferative potential, and their proliferative
capacity and synthetic capacity decline with age [8].
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Embryonic stem (ES) cells and induced pluripotent stem
(iPS) cells are thought to be an ideal cell source for tissue
regeneration. We reported that ES cells can be diﬀerentiated
into cartilage and used to repair defects when placed in a car-
tilage defect [9]. However, the use of these cells raises ethical
issues since ES cells are derived from fertilized human eggs.
On the other hand, there are no ethical issues associated with
the use of iPS cells because they are induced from mature
somatic cells, and a large number of cells can easily be col-
lected. A paper by Ko et al. reported the use of human iPS
cells implanted into cartilage defects and showed that the
defect was ﬁlled with good quality cartilage [10].
We reported that when ES cells were transplanted into
the knee joint, they formed tumors and destroyed the knee
joint in SCID mice [11]. However, when they were trans-
planted into an osteochondral defect, they did not generate
teratomas. These results demonstrate that it is important to
conﬁne the ES cells to the defect. It is conceivable that some
growth factors are released from bone marrow which pro-
mote the chondrogenesis of ES cells [9]. On the other hand,
Kamei et al. reported delivery of magnetically labeled mesen-
chymal stem cells into an osteochondral defect using a mag-
netic ﬁeld, resulting in good repair of the defects [12].
Consequently, we hypothesized that if magnetically labeled
iPS cells could be delivered speciﬁcally into cartilage defects
by magnetic ﬁeld, it would be possible to prevent the forma-
tion of teratomas and to repair articular cartilage. The pur-
pose of this study was to investigate the eﬃcacy and safety
of magnetic targeting of iPS cells for articular cartilage repair.
2. Materials and Methods
2.1. iPS Cell Preparation. Human iPS cells, derived from
human fetal lung cells (MRC-5) and infected with recombi-
nant retroviruses expressing the four reprogramming factors
(Oct3/4, Sox2, Klf4, and c-Myc), were purchased from the
National Institutes of Biomedical Innovation, Health and
Nutrition. The cell number is JCRB1331 [13].
Feeder cells were prepared from mouse primary
embryonic ﬁbroblasts (MEF) inactivated with mitomycin
C. The iPS cells were cultured on the feeder cells. The
medium (Serum-free Essential 8 Medium; Life Technologies,
California, USA) was changed every day.
2.2. Animals. Nine- to ten-week-old nude rats (F344/NJcl-
rnu/rnu) used in this study were purchased from CLEA
Japan Inc. (Tokyo, Japan). This study was approved by the
Committee of Research Facilities for Laboratory Animal Sci-
ence (Graduate School of Biomedical Science, Hiroshima
University), and rats were cared for according to the Guide
for Animal Experimentation.
2.3. External Magnetic Force. To deliver a magnetic ﬁeld, we
used a neodymium magnet (Sangyo Supply Inc., Miyagi,
Japan).
2.4. Magnetic Labeling of iPS Cells. Serum-free Essential 8
medium with 15% fetal bovine serum (FBS) and 1% antibi-
otic mixed stock solution (Nacalai Tesque Inc., Kyoto, Japan)
were equilibrated at 37°C under 5% CO2 for at least 30
minutes. Nanoscale iron particles (ferucarbotran; 27.9mg
Fe/mL) (Fujiﬁlm RI Pharma Co. Ltd., Tokyo, Japan) were
added to the solution at a concentration of 98.2mg Fe/mL.
The solution was agitated for 3 to 5 minutes by manual
shaking, then added to the iPS cells in the culture dish, and
cultured overnight. On the next day, the dish was washed
twice with sterile phosphate-buﬀered saline (PBS).
To purify magnetically labeled iPS cells, an external
magnet was placed beside the tube as the nonadherent mag-
netically labeled iPS cells were dropped into the culture
medium. The cells were separated into those attracted
towards the magnet and those that fell to the bottom. The
iPS cells drawn towards the magnet were denoted as m-iPS
cells, while the others were denoted as non-m-iPS cells. The
cell number in each group was counted.
2.5. Assessment of m-iPS Cells
2.5.1. Evaluating the Capture of Nanoscale Iron Particles into
iPS Cells. After magnetic labeling, culture medium was
removed and the dish was washed twice with PBS. The cells
were ﬁxed in 4% paraformaldehyde phosphate-buﬀered solu-
tion (Wako Pure Chemical Industries Ltd., Osaka, Japan) for
10 minutes at room temperature. The phosphate-buﬀered
paraformaldehyde solution was removed, and the dish was
washed with PBS, then dehydrated with 100% ethanol for
10 minutes, and dried in air after removing the ethanol.
The dish was stained with Berlin blue to show the presence
of iron.
2.5.2. Assessment of Pluripotency
(1) In Vitro Assessment. Embryoid bodies were formed as
follows. The m-iPS cells were singly dissociated and mixed
in primate ES cell medium (ReproCELL Inc., Kanagawa,
Japan) with 10μM Rho-associated protein kinase inhibitor
4-[(1R)-1-aminoethyl]-N-4-pyridinyl-trans-cyclohexanecar-
boxamide, dihydrochloride (Y-27632;Wako Pure Chemicals,
Osaka, Japan). The m-iPS cells were then seeded onto 96-well
plates at 1× 104 cells/well and centrifuged for 3 minutes.
After incubating for 3 weeks under a humidiﬁed atmosphere
of 5% CO2 at 37
°C, the formed pellets were cultured for 2
weeks, with medium changes every two days. The pellets
were then immunostained as follows: following ﬁxation of
the pellets with 4% paraformaldehyde phosphate-buﬀered
solution for 15min at 4°C, cells were permeabilized with
0.1% Triton X-100, washed with PBS containing 2% BSA,
and incubated with primary antibodies diluted in PBS con-
taining 2% BSA. Primary antibodies against βIII-tubulin
(Merck Millipore, Darmstadt, Germany), desmin (Thermo
Fisher Scientiﬁc Inc., Waltham, MA, USA), and α-fetopro-
tein (Merck Millipore) were detected using the secondary
antibodies Alexa-ﬂuor® 488-conjugated anti-mouse IgG
and Alexa-ﬂuor 488-conjugated anti-rabbit IgG (both from
Thermo Fisher Scientiﬁc Inc.). Cell nuclei were stained with
1μg/mL 4′,6-diamidino-2-phenylindole (DAPI) (Thermo
Fisher Scientiﬁc Inc.).
(2) In Vivo Assessment. Teratoma formation was evaluated as
follows. Nude rats were used as implant recipients in this
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study. Aliquots of 1× 108 m-iPS cells were percutaneously
implanted into the subcutaneous area. Once a tumor had
formed, the rats were humanely killed, and the tumor was
resected to assess tumor formation histologically. Tumors
were ﬁxed in 4% paraformaldehyde phosphate-buﬀered solu-
tion for 48 hours and then embedded in paraﬃn blocks. The
samples were cut into 5μm sections and stained with hema-
toxylin and eosin for histological assessment.
2.6. Surgery. To prepare for transplantation, a single cell sus-
pension of m-iPS cells was prepared and mixed in 3% atelo-
collagen (Koken, Tokyo, Japan) at 107 cells/mL. Nude rats
were used in this study. Before surgery, the rats were given
suﬃcient anesthesia by ketamine (100mg/kg) and xylazine
(12mg/kg) by intraperitoneal administration. The medial
parapatellar approach was used to expose the knee joint,
and a defect was created in the patellar groove using a
2mm steel round burr in both knees. The defect size was
2mm in both width and depth. The rats were randomly
divided into three groups. In the magnetic force group (M
group; n = 18), the knee defects were ﬁlled with m-iPS cells
(105 cells) which were drawn into the cartilage defect using
an external magnetic force for 10 minutes. The magnet was
located on popliteal fossa for drawing into defect. In the non-
magnetic force group (NM group; n = 18), the knee defects
were ﬁlled with iPS cells (105 cells) without the use of an
external magnetic force for 10 minutes. For the control group
(C group; n = 18), the defects were ﬁlled with atelocollagen
alone. At the completion of the surgery, the patella was repo-
sitioned, and the wound was closed. Six rats from each group
were humanely killed at each of the time points of 4, 6, and 8
weeks after surgery.
2.7. Histological Analyses. The distal femurs were excised and
ﬁxed in 4% paraformaldehyde phosphate-buﬀered solution
for 48 hours. The samples were decalciﬁed with ethylenedi-
aminetetraacetic acid (EDTA) solution and embedded in
paraﬃn blocks, which were cut into 5μm sections along the
axial plane, deparaﬃnized, and hydrated. For histological
assessment, the sections were stained with hematoxylin and
eosin and with safranin O. For immunohistological assess-
ment, the sections were stained with antibodies against type
II collagen and human mitochondria. For immunohisto-
chemical staining with antibodies against type II collagen
and human mitochondria, the sections were incubated with
10% immunoactive (Matsunami Glass Ind. Ltd., Osaka,
Japan) in PBS. The slides were blocked in hydrogen peroxide
solution (3%H2O2) for 10 minutes, followed by washing with
PBS. Primary antibodies were applied and incubated
Figure 1: Microscopic ﬁndings (Berlin blue stain) of iPS cells
labeled magnetically. Nanoscale iron particles were located inside
m-iPS cells. Scale bar = 200μm.
(a) (b)
(c) (d)
Figure 2: Microscopic ﬁndings of m-iPS cell pellets (a). The pellets
was evaluated by immunoﬂuorescent stain (b, c, and d). Ectoderm
maker alpha-fetoprotein (b), mesoderm maker desmin (c), and
endoderm maker beta III-tubulin (d) were expressed from the
pellets. So we succeeded in forming embryoid body derived from
the m-iPS cells. Scale bar = 500.
(a) (b)
(c) (d)
(e)
Figure 3: Tumor formation in nude rat in which m-iPS cells were
transplanted (a and b). The nude rat in which m-iPS cells were
transplanted showed tumor formation at 7 weeks after
transplantation (a). Macroscopically, the tumor was solid and
cystic and pressed the surrounding tissue outwards (b).
Histopathological ﬁndings (hematoxylin and eosin stain) of the
tumor (c, d, and e). The tumor contains immature neural tube (c),
immature glandular structure (d), and immature muscle (e). We
conclude that the tumor is immature teratoma. Scale bar = 300μm.
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overnight at 4°C. The antibody reaction procedures were
followed by a treatment with an avidin-conjugated peroxi-
dase (Vectastain ABC-Elite Lit, Vector Laboratories, Burlin-
game, California, USA), and then visualization was
performed using a 3,3′-diaminobenzidine (DAB) substrate
kit (Vector Laboratories). Each sample stained with antibod-
ies against type II collagen was graded according to the histo-
logic grading score for cartilage regeneration as described by
us and Pineda et al.
2.8. Statistical Analysis. All results are expressed as mean
± standard deviation. Statistical comparisons amongmultiple
groups were evaluated by the Kruskal-Wallis test, and a pair-
wise comparison was performed using the Mann–Whitney
test. A signiﬁcant diﬀerence was set at P < 0 05.
3. Results
3.1. Magnetic Labeling of iPS Cells. Staining showed that most
iPS cells had become magnetically labeled m-iPS cells
because nanoscale iron particles were located inside almost
all the iPS cells (Figure 1). Cell counts revealed that m-iPS
cells made up 93.1± 2.2% of the population while non-m-
iPS cells made up 6.9± 2.2% (P < 0001).
3.2. Assessment of Pluripotency
3.2.1. In Vitro Assessment. Immunoﬂuorescence staining
showed that the ectoderm marker alpha-fetoprotein
(Figure 2(b)), the mesoderm marker desmin (Figure 2(c)),
and the endoderm marker beta III-tubulin (Figure 2(d))
were expressed in the pellets. This conﬁrms that embryoid
bodies were successfully derived from the m-iPS cells.
These ﬁndings suggest that they have the ability to diﬀer-
entiate into three embryonic germ layers and that m-iPS
cells maintain pluripotency.
3.2.2. In Vitro Assessment. Seven rats were percutaneously
implanted with m-iPS cells into subcutaneous tissue, and
two rats showed tumor formation 7 weeks after implantation.
Macroscopically, each tumor was a mixture of cystic and
solid tissue (Figures 3(a) and 3(b)). Histologically, the tumor
was categorized as an immature teratoma, because it
contained neural tube (Figure 3(c)), glandular structure
(Figure 3(d)), and muscle (Figure 3(e)).
3.3. Assessment of Articular Cartilage Repair. After trans-
planting iPS cells embedded in collagen hydrogel into the
osteochondral defect of rats, no tumors were seen in the M
group. Macroscopic examination of a rat in the NM group
showed tumor formation in the knee joint and subcutaneous
space at 4 weeks after transplantation (Figure 4(a)). Histolog-
ically, the tumor extruded from the knee joint and was
thought to be a teratoma (Figure 4(b)).
At 4 weeks after transplantation in the M group, osteo-
chondral defects in the patellar groove of the femur were
covered by hyaline-like cartilage; however, the surface of
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Figure 4: Tumor formation in the knee joints and subcutaneous
spaces in the NM group at 4 weeks after transplantation.
Macroscopically, the tumor was solid and cystic (a).
Histopathological ﬁndings of the tumor (hematoxylin and eosin
stain, b and c). The tumor contains immature neuroepithelium
(∗), immature cartilage (∗∗), and immature mesenchymal elements
(∗∗∗). We conclude that the tumor is immature teratoma. Scale
bar = 2mm in (b) and 500μm in (c).
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Figure 5: In vivo cartilage repair at 4, 6, and 8 weeks after
transplantation. At 4 weeks after transplantation in the M group,
osteochondral defects in the patellar groove of the femur were
covered by hyaline-like cartilage; however, the surface of cartilage
was irregularity (a). At 6 and 8 weeks, defects were also covered by
hyaline-like cartilage, and the surface was smooth (b and c). On the
other hand, in the NM group and C group, osteochondral defects
could be not regenerated cartilage by 8 weeks (c). Scale bar = 500μm.
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the cartilage was irregular (Figure 5(a)). At 6 and 8 weeks,
all defects were covered by hyaline-like cartilage, and the
surface was smooth (Figures 5(b) and 5(c)). In contrast,
in the NM and C groups, osteochondral defects showed
no regenerated cartilage by 8 weeks (Figure 5(c)). In addition,
the mean histologic grading score, according to the
method of Wakitani, was signiﬁcantly better in the M
group than in the C group (at 4 weeks: P = 0 011; at 8
weeks: P = 0 005) (Figure 6(a)). Using the method of Pineda,
the score was signiﬁcantly better in the M group than in the
other groups (M and NM, at 4 weeks: P = 0 05; M and C, at
4 weeks: P = 0 002; M and NM, at 8 weeks: P = 0 04; M
and C, at 8 weeks: P = 0 008) (Figure 6(b)). In the M
group, immunoﬂuorescent staining showed that human
mitochondria were present in the cartilage cells. These
ﬁndings suggest that m-iPS cells diﬀerentiate into cartilage
cells (Figure 7).
4. Discussion
In this study, we found that the repair of cartilage defects
using m-iPS cells with application of an external magnetic
force was signiﬁcantly better than without the external
magnetic force. Furthermore, we found no evidence of tumor
formation in the knee joint transplanted with m-iPS cells
with external magnetic force, while those transplanted
without external magnetic force did show tumor forma-
tion. The results demonstrated that this system for deliv-
ery of iPS cells makes cartilage regeneration possible and
prevents teratoma formation.
We have shown that iPS cells can be magnetically labeled
with nanoscale iron particles and still maintain pluripotency,
demonstrated by the formation of embryoid bodies and tera-
tomas from m-iPS cells. There have been several previous
reports of iPS cells labeled magnetically. Castaneda and col-
laborators reported that iPS cells were labeled magnetically
using ferumoxytol and visualized with MR imaging [14].
Furthermore, Ruan and collaborators reported that embry-
oid bodies were formed from iPS cells labeled magnetically
and that these cells maintained pluripotency and diﬀerenti-
ated into three germ layers in vitro [15].
However, there has been no report of cartilage regenera-
tion using iPS cells labeled magnetically. This study is the ﬁrst
to evaluate the repair of a cartilage defect using iPS cells
labeled magnetically in combination with an external mag-
netic force. m-iPS cells were delivered to the cartilage defect
of the knee joint by an external magnetic ﬁeld, and the defect
was covered by hyaline-like cartilage. Conversely, when m-
iPS cells were transplanted into the defect without the use
of an external magnetic ﬁeld, the defect was not covered by
hyaline-like cartilage. In addition, the histologic grading
score for cartilage regeneration was signiﬁcantly better in
the former than in the latter. Uto and collaborators reported
transplanting iPS cells combined with collagen hydrogel into
an osteocartilage defect and found that the defects were
repaired [3]. They concluded that mixing iPS cells in collagen
(a) (b)
(c) (d)
Figure 7: Immunoﬂuorescent staining with antibodies against
human mitochondria (a, b, and c) and safranin O staining (d) of
cartilage cells. The antibodies against human mitochondria were
expressed from cartilage cells. These ﬁndings suggest that m-iPS
cells diﬀerentiate into cartilage cells. Bar = 50μm.
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Figure 6: The mean histologic grading score byWakitani and Pineda. The mean histologic grading score byWakitani was signiﬁcantly better
in the M group than in the C group (in 4 weeks: P = 0 011; in 8 weeks: P = 0 005). By Pineda, score was signiﬁcantly better in theM group than
in the other groups (M and NM, in 4 weeks: P = 0 05; M and C, in 4 weeks: P = 0 002; M and NM, in 8 weeks: P = 0 04; M and C, in 8 weeks:
P = 0 008). ∗P < 0 05.
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hydrogel could cause these cells to undergo a loss of cell-
cell contact, which forced the iPS cells to lose pluripotency
and undergo diﬀerentiation. In this study, m-iPS cells
embedded in atelocollagen were delivered into a cartilage
defect by an external magnetic ﬁeld and the cartilage
showed a good level of repair. However, when m-iPS cells
embedded in atelocollagen were transplanted without an
external magnetic ﬁeld, the cartilage repair was not as
good. We believe that the m-iPS cells were not drawn
toward the defect without the external magnetic ﬁeld; con-
sequently, fewer cells were present within the defect and
the cartilage repair was not as eﬀective.
Yamashita and collaborators reported that diﬀerentiation
of iPS cells into hyaline cartilaginous particles and implanta-
tion of the particles into joint surface defects in immunodeﬁ-
cient rats prevented teratoma formation. As a result, cartilage
defects were repaired and neither tumors nor ectopic tissue
formation was observed [16]. However, in vivo culture
expansion of cartilage stem cells is associated with disadvan-
tages including labor, high cost, the necessity for expensive
growth factors, and the risk of infection [17, 18]. We reported
that when ES cells were injected into the knee joint of SCID
mice, the cells formed teratomas. However, when the ES cells
were transplanted into osteochondral defects in the patellar
groove of immunosuppressed rats treated with cyclosporine,
no sign of tumor growth or nonchondrocyte tissue was
observed in the transplant recipients and the defects were
repaired with hyaline-like cartilage. The reasons may be that
cells in the joint space are fed by joint ﬂuid not by blood,
while on the other hand, those in an osteochondral defect
are fed by both joint ﬂuid and blood. Some growth factors
released from bone marrow promote the chondrogenesis of
ES cells [9]. In this study, m-iPS cells were delivered to a car-
tilage defect in the knee joint by an external magnetic ﬁeld
and moved to the bottom of cartilage defect, and no tumor
formation was observed. In contrast, when m-iPS cells were
transplanted into the defect without the use of an external
magnetic ﬁeld, teratoma formation was observed at seven
weeks after transplantation. The tumor appeared to be an
immature teratoma, based on histological analysis. We
believe that iPS cells diﬀerentiated into hyaline-like cartilage
or teratoma by the same mechanism as ES cells.
5. Conclusions
This study has demonstrated that magnetically labeled iPS
cells maintain pluripotency and that when they are delivered
to a cartilage defect by an external magnetic ﬁeld, they can
regenerate cartilage. In addition, the histologic grading score
in the M group was signiﬁcantly better than in the NM group
or in the C group, and no tumor formation was observed.
This method will be useful for cartilage repair using iPS cells.
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